Ionizable lipid nanoparticles (LNPs) are the most clinically advanced nano‐delivery system for therapeutic nucleic acids. The great effort put in the development of ionizable lipids with …
Conspectus Delivering nucleic acid-based therapeutics to cells is an attractive approach to target the genetic cause of various diseases. In contrast to conventional small molecule …
JD Finn, AR Smith, MC Patel, L Shaw, MR Youniss… - Cell reports, 2018 - cell.com
The development of clinically viable delivery methods presents one of the greatest challenges in the therapeutic application of CRISPR/Cas9 mediated genome editing. Here …
Genetic drugs such as small interfering RNA (siRNA), mRNA, or plasmid DNA provide potential gene therapies to treat most diseases by silencing pathological genes, expressing …
Hereditary genetic disorders, cancer, and infectious diseases of the liver affect millions of people around the globe and are a major public health burden. Most contemporary …
Onpattro, the first RNAi-based therapeutic to receive FDA approval, is enabled by a lipid nanoparticle (LNP) system that facilitates siRNA delivery into the cytoplasm of target cells …
JA Kulkarni, MM Darjuan, JE Mercer, S Chen… - ACS …, 2018 - ACS Publications
Lipid nanoparticles (LNPs) containing short interfering RNA (LNP-siRNA) and optimized ionizable cationic lipids are now clinically validated systems for silencing disease-causing …
H Liu, H Zhang, S Wang, J Cui, W Weng, X Liu… - Composites Part B …, 2023 - Elsevier
Osteoporosis (OP), characterized by decreased bone mass and destruction of bone microarchitecture, is the most common bone degenerative disease. Conventional treatments …
Lipid nanoparticles (LNPs) have emerged as a powerful non-viral carrier for drug delivery. With the prevalence of respiratory diseases, particularly highlighted by the current COVID-19 …